A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

225

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

April 30, 2027

Conditions

Asthma

Interventions

DRUG

610

Subcutaneously injection.

DRUG

610

Subcutaneously injection.

DRUG

Placebo

Subcutaneously injection.

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

NCT06680947 - A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma | Biotech Hunter | Biotech Hunter